
By Marketwired . | Article Rating: |
|
January 31, 2013 01:42 AM EST | Reads: |
387 |
BAGSVAERD, DENMARK -- (Marketwire) -- 01/31/13 -- Sales growth of 18% driven by Victoza®, NovoRapid® and Levemir® Sales increased by 18% to 78.0 billion in Danish kroner and by 12% in local currencies.
* Sales of modern insulins increased by 21% (15% in local currencies).
* Sales of Victoza® increased by 58% (50% in local currencies).
* Sales in North America increased by 29% (19% in local currencies).
* Sales in International Operations increased by 18% (16% in local currencies).
Reported operating profit increased by 32% to DKK 29.5 billion including a 1.7 percentage points improvement in the gross margin. Measured in local currencies, operating profit increased by 20%.
Company announcement No 8 / 2013: http://hugin.info/2013/R/1674355/545183.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Thomson Reuters ONE
[HUG#1674355]
CONTACTS FOR FURTHER INFORMATION
Media:
Mike Rulis
+45 4442 3573
Email Contact
Ken Inchausti (US)
+1 609 514 8316
Email Contact
Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact
Frank Daniel Mersebach
+45 4442 0604
Email Contact
Lars Borup Jacobsen
+45 3075 3479
Email Contact
Jannick Lindegaard (US)
+1 609 786 4575
Email Contact
Published January 31, 2013 Reads 387
Copyright © 2013 SYS-CON Media, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
More Stories By Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
![]() Apr. 24, 2018 11:30 PM EDT Reads: 3,719 |
By Pat Romanski ![]() Apr. 24, 2018 11:00 PM EDT Reads: 7,269 |
By Pat Romanski Apr. 24, 2018 11:00 PM EDT Reads: 2,865 |
By Elizabeth White ![]() Apr. 24, 2018 11:00 PM EDT Reads: 3,629 |
By Elizabeth White ![]() Apr. 24, 2018 11:00 PM EDT Reads: 5,350 |
By Liz McMillan ![]() Apr. 24, 2018 10:45 PM EDT Reads: 7,070 |
By Liz McMillan ![]() Apr. 24, 2018 10:45 PM EDT Reads: 1,560 |
By Liz McMillan ![]() Apr. 24, 2018 09:45 PM EDT Reads: 5,351 |
By Liz McMillan ![]() Apr. 24, 2018 09:30 PM EDT Reads: 22,741 |
By Liz McMillan ![]() Apr. 24, 2018 09:15 PM EDT Reads: 4,820 |
By Elizabeth White ![]() Apr. 24, 2018 09:15 PM EDT Reads: 1,277 |
By Elizabeth White ![]() Apr. 24, 2018 09:00 PM EDT Reads: 4,475 |
By Elizabeth White ![]() Apr. 24, 2018 09:00 PM EDT Reads: 9,266 |
By Elizabeth White ![]() Apr. 24, 2018 08:45 PM EDT Reads: 5,414 |
By Pat Romanski ![]() Apr. 24, 2018 08:45 PM EDT Reads: 4,035 |